#1 Clinical Trials Search in Europe

Pelareorep

Pelareorep, also known as Reolysin, is an innovative drug currently being studied in clinical trials for various advanced cancers, including breast cancer, non-small cell lung cancer, and prostate cancer. This article explores the ongoing research on Pelareorep, its potential benefits, and its combination with other cancer treatments to improve patient outcomes.

Table of Contents

What is Pelareorep?

Pelareorep, also known by its brand name Reolysin, is an innovative cancer treatment that is currently being studied in various clinical trials[1][2]. It is a type of oncolytic virus, which means it’s a virus that has been modified to target and destroy cancer cells while leaving healthy cells relatively unharmed[3].

How Does Pelareorep Work?

Pelareorep works by selectively infecting and killing cancer cells. Once inside the cancer cell, the virus replicates, causing the cell to burst and die. This process not only directly kills cancer cells but also stimulates the body’s immune system to recognize and attack cancer cells throughout the body[3].

What Conditions Does Pelareorep Treat?

Based on the clinical trials information provided, Pelareorep is being studied for the treatment of several types of advanced or metastatic cancers, including:

  • Advanced or Metastatic Breast Cancer: Several studies are focusing on the use of Pelareorep in combination with other drugs for breast cancer treatment[1][2].
  • Non-Small Cell Lung Cancer (NSCLC): Pelareorep is being tested in combination with standard chemotherapy drugs for previously treated advanced or metastatic NSCLC[3].
  • Metastatic Castration-Resistant Prostate Cancer: A study is evaluating the effectiveness of Pelareorep in combination with standard treatments for this advanced form of prostate cancer[4].

Current Clinical Trials

Several clinical trials are currently underway to evaluate the effectiveness and safety of Pelareorep:

  1. Breast Cancer Trial (NCT05519059): This is a Phase I study in China, combining Pelareorep with Paclitaxel in patients with advanced or metastatic breast cancer[1].
  2. Breast Cancer Trial (NCT01656538): A randomized Phase II study comparing Paclitaxel plus Pelareorep to Paclitaxel alone in advanced or metastatic breast cancer[2].
  3. Non-Small Cell Lung Cancer Trial (NCT01708993): A randomized Phase II study evaluating Pelareorep in combination with either Docetaxel or Pemetrexed for previously treated advanced or metastatic NSCLC[3].
  4. Prostate Cancer Trial (NCT01619813): A randomized Phase II study comparing Docetaxel and Prednisone with or without Pelareorep in metastatic castration-resistant prostate cancer[4].

How is Pelareorep Administered?

Pelareorep is typically administered intravenously (through a vein) in combination with other cancer treatments. The dosage and frequency can vary depending on the specific trial and condition being treated. For example:

  • In the breast cancer trial, Pelareorep is given at doses ranging from 1.5×10^10 to 4.5×10^10 TCID50 (a measure of virus concentration) on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle[1].
  • In the lung cancer trial, Pelareorep is administered at a dose of 4.5×10^10 TCID50 on days 1-3 of each 3-week cycle[3].

Potential Side Effects and Safety

As with any medical treatment, Pelareorep may cause side effects. The clinical trials are designed to assess the safety and tolerability of Pelareorep when combined with other cancer treatments. Common side effects observed in cancer treatments may include fatigue, nausea, and decreased blood cell counts. However, the specific side effects of Pelareorep are still being studied[1][2][3].

Future Research and Potential

The ongoing clinical trials aim to determine the effectiveness of Pelareorep in improving outcomes for patients with advanced cancers. Researchers are looking at various measures of efficacy, including:

  • Progression-free survival: The length of time during and after treatment that a patient lives with the disease without it worsening[2][3].
  • Overall survival: The length of time from the start of treatment that patients are still alive[1].
  • Objective response rate: The proportion of patients whose cancer shrinks or disappears after treatment[1].
  • Disease control rate: The percentage of patients whose cancer either shrinks or remains stable after treatment[1].

Additionally, researchers are exploring potential molecular factors that might predict which patients are most likely to respond to Pelareorep treatment[3][4]. This could help in personalizing treatment approaches in the future.

Aspect Details
Drug Name Pelareorep (also known as Reolysin)
Cancer Types Studied Advanced/metastatic breast cancer, non-small cell lung cancer, metastatic castration-resistant prostate cancer
Combination Therapies Paclitaxel, Docetaxel, Pemetrexed, Prednisone
Administration Intravenous infusion, typically in combination with other cancer drugs
Key Outcomes Measured Progression-free survival, objective response rate, disease control rate, overall survival, safety and tolerability
Additional Assessments Circulating tumor cells, molecular factors predictive of response
Trial Phases Phase I and Phase II studies

FAQ

  • What is Pelareorep? Pelareorep, also known as Reolysin, is a virus-based drug that has shown the ability to target and destroy cancer cells in laboratory tests. It is being studied in clinical trials for various advanced cancers.
  • Which types of cancer are being studied with Pelareorep? Pelareorep is being studied in clinical trials for advanced or metastatic breast cancer, non-small cell lung cancer, and metastatic castration-resistant prostate cancer.
  • How is Pelareorep administered in clinical trials? In the trials, Pelareorep is typically administered intravenously (through a vein) in combination with other cancer drugs. The dosage and frequency may vary depending on the specific trial and cancer type being studied.
  • What are the potential benefits of combining Pelareorep with other cancer treatments? Researchers are investigating whether combining Pelareorep with standard cancer treatments like paclitaxel, docetaxel, or pemetrexed can offer better results than these treatments alone. The goal is to improve outcomes such as progression-free survival and overall survival for patients with advanced cancers.
  • What are some of the outcomes being measured in Pelareorep clinical trials? Clinical trials are measuring various outcomes, including progression-free survival, objective response rate, disease control rate, duration of response, overall survival, and the number of patients experiencing adverse events. Some trials are also exploring potential molecular factors that may predict treatment response.

Ongoing Clinical Trials on Pelareorep

  • Study on Pelareorep and Atezolizumab for Patients with Advanced or Metastatic Gastrointestinal Cancers

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Pelareorep: A virus-based drug, also known as Reolysin, that targets and destroys cancer cells. It is being studied in clinical trials for various advanced cancers.
  • Metastatic cancer: Cancer that has spread from its original site to other parts of the body.
  • Progression-free survival: The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Objective response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Disease control rate (DCR): The percentage of patients whose cancer shrinks, disappears, or remains stable after treatment.
  • Overall survival (OS): The length of time from the start of treatment until death from any cause.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a decrease in dosage.
  • TCID50: A measure of virus concentration, standing for 'Tissue Culture Infectious Dose 50%'. It represents the amount of virus required to produce a cytopathic effect in 50% of inoculated tissue culture cells.
  • Circulating tumor cells (CTCs): Cancer cells that have detached from a tumor and are found in the bloodstream.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a set of rules used to assess how well a cancer patient responds to treatment.

References

  1. https://clinicaltrials.gov/study/NCT05519059
  2. https://clinicaltrials.gov/study/NCT01656538
  3. https://clinicaltrials.gov/study/NCT01708993
  4. https://clinicaltrials.gov/study/NCT01619813